Earnings ·
Aptevo Therapeutics Inc. reported financial results for the quarter ended June 30, 2026, highlighting strong clinical…
APVOAptevo Therapeutics Inc.
Aptevo Therapeutics Inc. reported financial results for the quarter ended June 30, 2026, highlighting strong clinical data for its lead candidate mipletamig in frontline acute myeloid leukemia (AML). The RAINIER trial showed an 87% clinical benefit rate and 81% remission rate across 31 evaluable patients. The company secured a $1.5 million non-dilutive grant to advance APVO451, appointed Mary J. Janatpour as Chief Scientific Officer, and entered a 50/50 collaboration with Niowave for radiopharmaceutical development. Cash and cash equivalents totaled $9.8 million at quarter-end. Aptevo Therapeutics Inc. is a clinical-stage biotechnology company developing novel multispecific immunotherapies for the treatment of cancer.